Product image of Lerin (Leuprorelin) supplied by GNH India

Lerin

Active Ingredient:
Leuprorelin
Origin:
EU

Lerin (Leuprorelin)

Leuprorelin, the active ingredient in Lerin, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as an implant for subcutaneous implantation use. It modulates the hypothalamic‑pituitary‑gonadal axis and is indicated for hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids and precocious puberty in appropriate patient populations.

GNH India supplies Lerin as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide under EU‑quality standards. Our distribution network ensures timely delivery and regulatory compliance for each shipment.

Manufacturer / TM Owner

Sandoz D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leuprorelin is a GnRH agonist used in the management of hormone‑dependent diseases.

  • Prostate cancer: reduces testosterone levels to slow tumor growth.
  • Endometriosis: suppresses estrogen production to alleviate pelvic pain and lesion progression.
  • Uterine fibroids: decreases ovarian hormone stimulation, leading to fibroid size reduction and symptom improvement.
  • Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis, allowing normal growth and development.

How It Works

  • Leuprorelin is a synthetic analogue of GnRH that binds with high affinity to pituitary GnRH receptors. Initial binding causes a transient surge in luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, followed by receptor desensitization and down‑regulation. This sustained suppression markedly lowers LH and FSH secretion, leading to reduced production of sex steroids such as testosterone and estradiol, which underpins its therapeutic effect in hormone‑sensitive conditions.

Side Effects

Leuprorelin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Hot flashes: transient episodes of warmth and sweating.
  • Injection site reactions: pain, erythema or swelling at the implant site.
  • Decreased libido: reduced sexual desire.
  • Fatigue: persistent tiredness.
  • Mood changes: irritability or mild depression.

Serious or Rare Side Effects

  • Cardiovascular events: hypertension, myocardial infarction or stroke.
  • Bone mineral density loss: increased risk of osteoporosis.
  • Severe allergic reactions: anaphylaxis or angioedema.
  • Liver function abnormalities: elevated transaminases.
  • Pituitary apoplexy: rare hemorrhage in the pituitary gland.

Precautions & Warnings

Before initiating leuprorelin therapy, clinicians should consider several precautionary measures to ensure patient safety.

  • Cardiovascular assessment: evaluate history of heart disease or hypertension.
  • Bone health monitoring: assess baseline bone mineral density and consider supplementation.
  • Diabetes screening: monitor glucose levels as hormone changes may affect glycemic control.
  • Pregnancy potential: avoid use in women of childbearing potential unless contraception is assured.
  • Drug interactions: review concomitant medications that may influence hormone levels.
  • Store at ambient temperature: keep the implant in its original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Leuprorelin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Antiestrogen therapy: may counteract leuprorelin’s hormone suppression.
  • CYP3A4 inducers: strong inducers could reduce leuprorelin exposure.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: hormonal changes may affect clotting risk, requiring INR monitoring.
  • Glucocorticoids: may increase risk of bone loss when combined.
  • Thyroid hormone replacement: adjust dose as hormone levels shift.
  • Antidepressants (SSRIs): monitor mood changes due to overlapping side‑effect profiles.

Frequently Asked Questions

Lerin, containing leuprorelin, is prescribed for hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids and precocious puberty. It works by suppressing the production of sex hormones that drive the growth of these diseases.

Leuprorelin is a synthetic GnRH analogue that initially stimulates, then desensitizes pituitary GnRH receptors. This leads to a sustained fall in luteinizing hormone and follicle‑stimulating hormone, which in turn sharply reduces testosterone and estrogen production, limiting hormone‑driven disease activity.

The dose of Lerin is determined by the prescribing clinician based on the specific indication, patient characteristics and treatment protocol. Dosage regimens vary and should follow the healthcare professional’s prescription.

Leuprorelin is generally contraindicated in pregnancy because it suppresses sex hormone production essential for fetal development. Its safety during breastfeeding has not been established, so use is avoided unless the benefits clearly outweigh the risks and under medical supervision.

To request Lerin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Lerin (leuprorelin) is similar to other GnRH agonists such as goserelin and triptorelin in mechanism and clinical use. Differences may lie in formulation (implant vs. depot injection), dosing intervals and manufacturer‑specific excipients, but overall efficacy and safety profiles are comparable when used as directed.

Lerin should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the implant from moisture, direct sunlight and extreme temperature fluctuations to maintain product stability.

Lerin is supplied as a sterile implant that is placed subcutaneously by a qualified healthcare professional. The implant releases leuprorelin over a defined period, providing continuous hormone suppression without the need for daily dosing.

Serious risks include cardiovascular events such as hypertension or stroke, significant loss of bone mineral density leading to osteoporosis, severe allergic reactions (anaphylaxis), and rare hepatic dysfunction. Patients should be monitored regularly for these complications.

Lerin is not recommended for individuals with known hypersensitivity to leuprorelin or any excipients, patients with uncontrolled cardiovascular disease, severe osteoporosis, or those who are pregnant or may become pregnant without effective contraception.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Leuprorelin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT